DelveInsight projects the generalized myasthenia gravis (gMG) market across the seven major markets (7MM) to expand significantly through 2034, underpinned by the launch of FABHALTA (iptacopan). In 2024 the 7MM recorded roughly 205,000 diagnosed gMG cases, with an anticipated compound annual growth rate during 2025–2034 driven by population aging, improved diagnosis and novel therapies. Iptacopan, an oral complement Factor B inhibitor in Phase III trials for refractory anti-AChR-positive gMG, is slated for a data submission by 2027 and carries first-in-class potential by blocking upstream complement activation. Novartis expects this mechanism-driven approach to capture a leading share of the evolving market, especially in the United States where gMG treatment spend currently outpaces EU4, UK and Japan combined.

Novartis has secured an exclusive worldwide license from Zonsen PepLib Biotech for a proprietary peptide-based radioligand therapy (RLT) asset. Under the agreement, Novartis paid an upfront fee of USD 50 million and may remit additional development, regulatory and sales milestones, plus tiered royalties on global net sales. The deal leverages PepLib’s proprietary peptide libraries and positions Novartis to augment its existing RLT portfolio, accelerating the candidate into late-stage development. This transaction underscores Novartis’ strategic commitment to expand its oncology franchise by integrating next-generation targeted radiopharmaceuticals.

According to Zacks’ proprietary Style Scores, Novartis stands out in the value category thanks to its attractive price-to-earnings valuation relative to peers, coupled with solid earnings stability metrics. The company’s consistent free cash flow generation—in excess of USD 9 billion annually—and a dividend yield in the upper quintile of the pharmaceutical sector contribute to a top quintile Value Score. Equity analysts highlight that generic competition in older franchises is being offset by the gMG and oncology pipelines, supporting long-term upside potential.